42 related articles for article (PubMed ID: 9698563)
1. Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.
Davé E; Adams R; Zaccheo O; Carrington B; Compson JE; Dugdale S; Airey M; Malcolm S; Hailu H; Wild G; Turner A; Heads J; Sarkar K; Ventom A; Marshall D; Jairaj M; Kopotsha T; Christodoulou L; Zamacona M; Lawson AD; Heywood S; Humphreys DP
MAbs; 2016 Oct; 8(7):1319-1335. PubMed ID: 27532598
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis of the Bivalency of the TRPV1 Agonist DkTx.
Ramanujam V; Crawford T; Cristofori-Armstrong B; Deuis JR; Jia X; Maxwell MJ; Jami S; Ma L; Vetter I; Mobli M
Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202314621. PubMed ID: 37953402
[TBL] [Abstract][Full Text] [Related]
3. Correction to Lancet Rheumatol 2019; 1: e23-34.
Lancet Rheumatol; 2019 Dec; 1(4):e205. PubMed ID: 38229373
[No Abstract] [Full Text] [Related]
4. TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life.
Davé E; Durrant O; Dhami N; Compson J; Broadbridge J; Archer S; Maroof A; Whale K; Menochet K; Bonnaillie P; Barry E; Wild G; Peerboom C; Bhatta P; Ellis M; Hinchliffe M; Humphreys DP; Heywood SP
MAbs; 2023; 15(1):2160229. PubMed ID: 36788124
[TBL] [Abstract][Full Text] [Related]
5. Simulation and Stability Assessment of Anti-EpCAM Immunotoxin for Cancer Therapy.
Hosseinian SA; Haddad-Mashadrizeh A; Dolatabadi S
Adv Pharm Bull; 2018 Aug; 8(3):447-455. PubMed ID: 30276141
[No Abstract] [Full Text] [Related]
6. Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.
Wei J; Bera TK; Liu XF; Zhou Q; Onda M; Ho M; Tai CH; Pastan I
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3501-E3508. PubMed ID: 29581296
[TBL] [Abstract][Full Text] [Related]
7. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
8. Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer.
Cai Y; Zhang J; Lao X; Jiang H; Yu Y; Deng Y; Zhong J; Liang Y; Xiong L; Deng N
Cancer Sci; 2016 Aug; 107(8):1141-50. PubMed ID: 27251178
[TBL] [Abstract][Full Text] [Related]
9. Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.
Tang J; Li J; Zhu X; Yu Y; Chen D; Yuan L; Gu Z; Zhang X; Qi L; Gong Z; Jiang P; Yu J; Meng H; An G; Zheng H; Yang L
Oncotarget; 2016 Jun; 7(23):34070-83. PubMed ID: 27083001
[TBL] [Abstract][Full Text] [Related]
10. Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.
Dengl S; Sustmann C; Brinkmann U
Immunol Rev; 2016 Mar; 270(1):165-77. PubMed ID: 26864111
[TBL] [Abstract][Full Text] [Related]
11. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
12. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
[TBL] [Abstract][Full Text] [Related]
13. Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli.
Liu J; Yang M; Wang J; Xu Y; Wang Y; Shao X; Yang C; Gao Y; Xiong D
Cancer Immunol Immunother; 2009 Nov; 58(11):1761-9. PubMed ID: 19259665
[TBL] [Abstract][Full Text] [Related]
14. Homology modelling and bivalent single-chain Fv construction of anti-HepG2 single-chain immunoglobulin Fv fragments from a phage display library.
Ni M; Yu B; Huang Y; Tang Z; Lei P; Shen X; Xin W; Zhu H; Shen G
J Biosci; 2008 Dec; 33(5):691-7. PubMed ID: 19179757
[TBL] [Abstract][Full Text] [Related]
15. A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax.
Vuyisich M; Gnanakaran S; Lovchik JA; Lyons CR; Gupta G
Protein J; 2008 Aug; 27(5):292-302. PubMed ID: 18649128
[TBL] [Abstract][Full Text] [Related]
16. SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.
Kimchi-Sarfaty C; Vieira WD; Dodds D; Sherman A; Kreitman RJ; Shinar S; Gottesman MM
Cancer Gene Ther; 2006 Jul; 13(7):648-57. PubMed ID: 16498428
[TBL] [Abstract][Full Text] [Related]
17. Disulfide-stabilized single-chain antibody-targeted superantigen: construction of a prokaryotic expression system and its functional analysis.
Wang JL; Zheng YL; Ma R; Wang BL; Guo AG; Jiang YQ
World J Gastroenterol; 2005 Aug; 11(31):4899-903. PubMed ID: 16097068
[TBL] [Abstract][Full Text] [Related]
18. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.
Bera TK; Onda M; Brinkmann U; Pastan I
J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563
[TBL] [Abstract][Full Text] [Related]
19. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
Kuan CT; Pastan I
Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
